What is claimed is:

1. Use of an interleukin-4 receptor (IL-4R) antagonist wherein the IL-4R antagonist is an antibody or antigen-binding fragment thereof that binds IL-4Ra and prevents the interaction of IL-4 and/or IL-13 with a type 1 or type 2 IL-4 receptor for the production of a medicament for treating, preventing or reducing the severity of an allergic reaction triggered by consumption of or exposure to a non-food item by a subject, wherein the antibody or antigen-binding fragment thereof comprises three HCDRs (HCDR1, HCDR2 and HCDR3) and three LCDRs (LCDR1, LCDR2 and LCDR3), wherein the HCDR1 comprises the amino acid sequence of SEQ ID NO:3, the HCDR2 comprises the amino acid sequence of SEQ ID NO:4, the HCDR3 comprises the amino acid sequence of SEQ ID NO:5, the LCDR1 comprises the amino acid sequence of SEQ ID NO:6, the LCDR2 comprises the amino acid sequence of SEQ ID NO:7, and the LCDR3 comprises the amino acid sequence of SEQ ID NO:8.

2. Use of an interleukin-4 receptor (IL-4R) antagonist wherein the IL-4R antagonist is an antibody or antigen-binding fragment thereof that binds IL-4Ra and prevents the interaction of IL-4 and/or IL-13 with a type 1 or type 2 IL-4 receptor for the production of a medicament for enhancing the efficacy and/or safety of an allergen-specific immunotherapy (SIT) regimen wherein the SIT regimen comprises administration of a non-food allergen derived from a non-food item selected from the group consisting of dust, pollen, insect venom, mold, animal fur, animal dander, wool, latex, metals, household cleaners, detergents, drugs, therapeutic monoclonal antibodies, ragweed, grass and birch, wherein the antibody or antigen-binding fragment thereof comprises three HCDRs (HCDR1, HCDR2 and HCDR3) and three LCDRs (LCDR1, LCDR2 and LCDR3), wherein the HCDR1 comprises the amino acid sequence of SEQ ID NO:3, the HCDR2 comprises the amino acid sequence of SEQ ID NO:4, the HCDR3 comprises the amino acid sequence of SEQ ID NO:5, the LCDR1 comprises the amino acid sequence of SEQ ID NO:6, the LCDR2 comprises the amino acid sequence of SEQ ID NO:7, and the LCDR3 comprises the amino acid sequence of SEQ ID NO:8, and wherein the antibody or antigen-binding fragment thereof is formulated in a medicament for administration to a subject prior to or concurrent with the SIT regimen.

3. Use of an interleukin-4 receptor (IL-4R) antagonist wherein the IL-4R antagonist is an antibody or antigen-binding fragment thereof that binds IL-4Ra and prevents the interaction of IL-4 and/or IL-13 with a type 1 or type 2 IL-4 receptor for the production of a medicament for reducing total serum IgE levels in a subject who has been exposed to an

allergen wherein the allergen is a non-food allergen derived from or contained within a non-food item selected from the group consisting of dust, pollen, insect venom, mold, animal fur, animal dander, wool, latex, metals, household cleaners, detergents, drugs, therapeutic monoclonal antibodies, ragweed, grass and birch, wherein the antibody or antigen-binding fragment thereof comprises three HCDRs (HCDR1, HCDR2 and HCDR3) and three LCDRs (LCDR1, LCDR2 and LCDR3), wherein the HCDR1 comprises the amino acid sequence of SEQ ID NO:3, the HCDR2 comprises the amino acid sequence of SEQ ID NO:4, the HCDR3 comprises the amino acid sequence of SEQ ID NO:5, the LCDR1 comprises the amino acid sequence of SEQ ID NO:6, the LCDR2 comprises the amino acid sequence of SEQ ID NO:7, and the LCDR3 comprises the amino acid sequence of SEQ ID NO:8, and wherein said antibody or antigen-binding fragment thereof is formulated in a medicament for administration to the subject in an amount sufficient to reduce or abrogate IgE production.

4. The use according to any one of claims 1 to 3, wherein the HCVR comprises the amino acid sequence of SEQ ID NO: 1 and the LCVR comprises the amino acid sequence of SEQ ID NO: 2.

5. The use according to any one of claims 1 to 4, wherein the IL-4R antagonist is dupilumab.

6. The use according to any one of claims 1, 4 and 5, wherein the antibody or antigen-binding fragment thereof is formulated in a medicament for administration to the subject before non-food allergen exposure.

7. The use according to any one of claims 1, 4 and 5, wherein the antibody or antigen-binding fragment thereof is formulated in a medicament for administration to the subject less than 4 hours before non-food allergen exposure.

8. The use according to any one of claims 1, 4 and 5, wherein the antibody or antigen-binding fragment thereof is formulated in a medicament for administration to the subject during or after non-food allergen exposure.

9. The use according to any one of claims 1, 4 to 8, wherein the antibody or antigen-binding fragment thereof is formulated in a medicament for administration to the subject less than 4 hours after non-food allergen exposure.

10. The use according to any one of claims 1, 4 to 8,, wherein the antibody or antigen-binding fragment thereof is formulated in a medicament for administration to the subject following the manifestation of one or more allergic symptoms in the subject.

11. The use according to any one of claims 1, 4 to 10, wherein the antibody or antigen-binding fragment thereof is formulated in a medicament for administration to the subject less than 4 hours after manifestation of one or more allergic symptoms in the subject.

12. The use according to any one of claims 1, 4 to 11, wherein the allergic symptoms are selected from the group consisting ofurticaria, angioedema, rhinitis, asthma, vomiting, respiratory compromise, swollen lips, swollen tongue, and reduced blood pressure.

13. The use of claim 1, wherein the allergic reaction is anaphylaxis.

14. The use according to any one of claims 1, 4 to 13, wherein the antibody or antigen-binding fragment thereof is formulated in a medicament for administration to the subject as part of a therapeutic dosing regimen comprising once a week, once every two weeks, once every three weeks, or once a month dosing.

15. The use according to any one of claims 1, 2, 4 to 14, wherein the antibody or antigen-binding fragment thereof is formulated in a medicament for administration to the subject in combination with a second therapeutic agent selected from the group consisting of steroids, antihistamines, decongestants, and anti-IgE agents.

16. The use according to any one of claims 2, 4 and 5, wherein the SIT regimen comprises an up-dosing phase followed by a maintenance phase.

17. The use according to any one of claims 2, 4, 5 and 16, wherein the SIT regimen is a rush SIT regimen.

18. The use according to any one of claims 1 to 17, wherein the antibody or antigen-binding fragment thereof is formulated in a medicament for administration to the subject in an amount from 0.5 mg to 600 mg.

19. The use according to claim 18, wherein the antibody or antigen-binding fragment thereof is formulated in a medicament for administration to the subject in an amount of 300 mg.

20. The use according to any one of claims 1 to 19, wherein the medicament is formulated to deliver the IL-4R antagonist subcutaneously.

21. The use according to any one of claims 1 to 20, wherein:
(a) the medicament is contained in a syringe; (b)the medicament is contained in a pen delivery device; or (c) the medicament is contained in a prefilled pen delivery device.